🇺🇸 FDA
Patent

US 8066985

Reovirus for the treatment of cellular proliferative disorders

granted A61KA61K35/765A61K9/0019

Quick answer

US patent 8066985 (Reovirus for the treatment of cellular proliferative disorders) held by ONCOLYTICS BIOTECH INC. expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ONCOLYTICS BIOTECH INC.
Grant date
Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K35/765, A61K9/0019, A61P, A61P31/12